Cardiome Delays Disclosure of Interim Vernakalant Data

Canadian drugmaker Cardiome is delaying the release of the interim results from its Phase IIb trial for vernakalant.

The double-blind, placebo-controlled, randomized, dose-ranging trial for the maintenance of normal heart rhythm following atrial fibrillation began earlier this year. Cardiome had intended to complete the analysis in the fourth quarter of 2007 but has decided to disclose study data in March 2008.

Doug Janzen, Cardiome’s president and chief business officer, said the delay will allow data from 20 percent more patients to be added to the analysis.